BeOne Medicines Ltd. — Director's Dealing 2023

Jun 21, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2023-06-15

Reporting Person: Lee Chan Henry (SVP, General Counsel)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	116012	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Share Option (Right to Buy)	$14.96	2032-08-04	Ordinary Shares (188929.0)		Direct

Footnotes

F1: Represents shares underlying unvested restricted share units. Unvested securities are subject to accelerated vesting upon certain termination events.

F2: These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.